QTTB

Q32 Bio Inc. 10-Q Summary: Period Ended June 30, 2026

Business Context and Reporting Period

This is a Quarterly Report on Form 10-Q for Q32 Bio Inc. (Nasdaq: QTTB) for the period ended June 30, 2026. Q32 is a clinical-stage biotechnology company focused on developing therapies for alopecia areata (AA) and other autoimmune diseases. The company's lead asset is bempikibart (ADX-914), an anti-IL-7Rα antibody currently in Phase 2 clinical trials. The company is classified as a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Significant Capital Raises: The company raised approximately $77.2 million in net proceeds during the six months ended June 30, 2026, through a Registered Direct Offering ($10.4 million), a Private Placement ($53.4 million), and an At-The-Market (ATM) offering ($13.5 million). This contrasts with no financing activity in the same period of 2025.
• Debt Elimination: On June 24, 2026, the company paid off its remaining venture debt balance of approximately $6.8 million, resulting in a $0.1 million loss on extinguishment of debt. As of June 30, 2026, the company has no outstanding debt.
• Reduced R&D Spend: R&D expenses decreased by $4.8 million year-over-year, primarily due to the sale of the ADX-097 asset to Akebia Therapeutics in November 2025, which eliminated associated development costs.
• Asset Sale Proceeds: The company received a $3.0 million payment from Akebia Therapeutics in May 2026 related to the ADX-097 asset sale.
• Equity Restructuring: The company resolved a $55.0 million refund liability related to a prior collaboration with Horizon/Amgen by issuing equity, which improved stockholders' equity and restored compliance with Nasdaq listing requirements.

Guidance, Outlook, and Risks

• Clinical Progress: In July 2026, the company announced topline results from the SIGNAL-AA Part B Phase 2a trial for bempikibart. Results showed a mean percent reduction in SALT score of 35.3% and 40% of patients achieving SALT20 response. The company plans to advance bempikibart into a registration-directed program in the first half of 2027.
• Liquidity Outlook: Management expects that cash on hand ($106.3 million) combined with proceeds from a subsequent Follow-On Financing (completed July 16, 2026, raising $187.6 million) will fund operations through topline Phase 3 results of bempikibart.
• Going Concern: While the company has significant cash reserves, it has incurred recurring losses since inception and expects to continue doing so. Future viability depends on raising additional capital for commercialization.
• Key Risks:
  • Dependence on the success of bempikibart; failure in clinical trials would materially harm the business.
  • Need for substantial additional capital to fund Phase 3 trials and commercialization.
  • Reliance on third-party manufacturers (CDMOs) and potential supply chain disruptions, including risks related to the BIOSECURE Act regarding Chinese vendors.
  • Intellectual property risks, including reliance on licenses from Bristol-Myers Squibb (BMS).

Investor Verification Checklist

• Follow-On Financing Terms: Verify the final terms and dilution impact of the $187.6 million Follow-On Financing completed in July 2026 (post-period).
• Phase 3 Trial Design: Confirm the specific design, patient enrollment targets, and estimated costs for the planned registration-directed Phase 3 program for bempikibart.
• Manufacturing Agreements: Review contracts with CDMOs to assess exposure to the BIOSECURE Act and potential supply chain disruptions.
• BMS License Obligations: Verify current milestone payment obligations and royalty rates under the Bristol-Myers Squibb license agreement.
• Cash Burn Rate: Monitor quarterly operating cash burn to validate the runway estimate through Phase 3 topline results.